Predictors of response in initial users of metformin and sulphonylurea derivatives: A systematic review

Diabetic Medicine

Volumn 32, Issue 7, 2015, Pages 853-864

  Martono, Doti P ^a,c   Lub, R ^a   Lambers Heerspink, H J ^b   Hak, E ^a   Wilffert, B ^a,b   Denig, P ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c BANDUNG INSTITUTE OF TECHNOLOGY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGE; ALBUMINURIA; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE DURATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY FUNCTION; MEDICATION COMPLIANCE; META ANALYSIS; PATIENT COMPLIANCE; PREDICTION; REVIEW; SAMPLE SIZE; SMOKING; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT RESPONSE; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG RESISTANCE; HYPERGLYCEMIA; MULTIDRUG RESISTANCE; PERSONALIZED MEDICINE;

DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; PRECISION MEDICINE; SULFONYLUREA COMPOUNDS;

EID: 84936931731     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12688     Document Type: Review

References (30)

1. Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin 2010; 26: 2127-2135.
2. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med 2007; 24: 350-358.
3. Cantrell RA, Alatorre CI, Davis EJ, Zarotsky V, Le Nestour E, Carter GC et al. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab 2010; 12: 845-857.
4. Sherifali D, Nerenberg K, Ullenayegum EP, Cheng JE, Gerstein HC. The Effect of Oral Antidiabetic Agents on A1C Levels: A systematic review and meta-analysis. Diabetes Care 2010; 33: 1859-1864.
5. Bennett WL, Maruthur N, Singh S, Segal JB, Wilson L, Chatterjee R et al. Comparative effectiveness and safety of medications for type 2 diabetes: An updated systematic review including new drugs and two-drug combinations. J Gen Intern Med 2011; 26: S69.
6. Koga M, Murai J, Saito H, Kasayama S. Prediction of near-future HbA1c levels using glycated albumin levels before and after glimepiride administration for 2 weeks is useful to determine the effectiveness of the treatment. Diabetol Int 2012; 3: 197-201.
7. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-261.
8. Sumitani S, Morita S, Utsu Y, Mukai K, Miki S, Sato B et al. Effectiveness of metformin and lifestyle interventions as an initial treatment in Japanese patients with newly diagnosed type 2 diabetes: a prospective observational study. J Med Investig 2012; 59: 166-173.
9. Shimizu H, Monden T, Nagai T, Shoda Y, Sato T, Yamada M et al. Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone. Diabet Med 2005; 22: 225-226.
10. Iranparvar M, Sadeghi-Bazargani H, Khodamoradzadeh M. The first research challenge for Diamicron MR in Iranian diabetic patients. Int J Pharmacol 2006; 2: 316-319.
11. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res 2009; 41: 905-909.
12. Donnelly LA, Doney ASF, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med 2006; 23: 128-133.
13. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009; 11: 804-812.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
15. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Last accessed 25 March 2013.
16. Drzewoski J, Czupryniak L. Long-term efficacy of steady-dose metformin in type 2 diabetes mellitus: a retrospective study. Med Sci Monit 2003; 9: CR240-3.
17. Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin 2010; 26: 2127-2135.
18. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2003; 57: 6-14.
19. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003; 284: E7-12.
20. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
21. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-70.
22. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucoselowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29: 2137-2139.
23. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials. Ann Intern Med 2011; 154: 554-559.
24. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
25. Ceriello A, Gallo M, Armentano V, Perriello G, Gentile S, De Micheli A. Personalizing treatment in type 2 diabetes: a selfmonitoring of blood glucose inclusive innovative approach. Diabetes Technol Ther 2012; 14: 373-378.
26. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006; 29: 504-509.
27. Garber AJ. Using dose-response characteristics of therapeutic agents for treatment decisions in type 2 diabetes. Diabetes Obes Metab 2000; 2: 139-147.
28. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
29. Hurren KM, Bartley EP, O'Neill JL, Ronis DL. Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes. Acta Diabetol 2013; 50: 261-265.
30. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J 2006; 174: 169-174.